This is a working overview of Ac-SDKP, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-24. Anything still debated is marked as such rather than presented as settled.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
== Exquisite Creatures exhibition == Marley developed a traveling exhibit of his artwork using preserved animal specimens from places such as Tanzania and Cambodia. The exhibit has traveled to museums such as North Carolina Museum of Natural Sciences, Oregon Museum of Science and Industry, and the Los Angeles County Museum of Art.
=== Pharmacokinetics === The metabolism of 4-HO-MET has been studied. In vitro experiments using pooled human liver microsomes identified twelve metabolites. Four metabolites were detected in vivo from human urine, of which two were detected in vitro.
By the time of nominations closing in April 2026, however, Galloway was no longer standing as a constituency candidate in Glasgow Southside, though remained on the regional ballot. He was unsuccessful, as were all other Workers Party candidates in the election. On 27 September 2025, while returning from Moscow through Abu Dhabi, George Galloway and his wife Putri Gayatri Pertiwi were stopped and questioned at Gatwick Airport by the Metropolitan Police's Counter Terrorism Command under the Counter-Terrorism and Border Security Act 2019 and questioned on his opinions of Russia, and China. His party condemned this as "politically motivated intimidation". The Metropolitan Police said "Neither of them were arrested and they were allowed on their way". Following the arrest Galloway entered a "self-imposed exile" in Russia. On the 4 September 2026, the Bank of Scotland closed Galloway's account prompting him to condemn the bank on X, saying "I will not stand by while you use your usurious power to wreck my family life." on the matter. In preparation for the 2026 Greater Manchester mayoral by-election, Galloway announced his candidacy on 19 June 2026. However, when nominations were released on 6 July, he was not listed as a candidate and was not included on the ballot. On the 14 September 2026 George Galloway announced his intention to stand in the 2026 Holborn and St. Pancras by-election on his podcast, MOATS.
Sources: en.wikipedia.org
== Production == Ron Shapiro – executive producer, A&R James Hunter – A&R Patrick Leonard – producer arrangements Duncan Sheik – co-producer arrangements Michele Arifty – personal assistant to Patrick Leonard Lisa Marie – representative Suzanne Ybarra – representative Moir/Marie Entertainment – representation company Jim Goodkind – legal affairs Loeb & Loeb – legal affairs Katrina Leigh – project coordinator Lynn Kowalewski – art direction Allen Hori – design Philippe McClelland – photography Technical credits
A month later, in May 1949, Thomas and his family moved to his final home, the Boat House at Laugharne, purchased for him at a cost of £2,500 in April 1949 by Margaret Taylor. Thomas acquired a garage a hundred yards from the house on a cliff ledge which he turned into his writing shed, and where he wrote several of his most acclaimed poems. He also rented "Pelican House" opposite his regular drinking den, Brown's Hotel, for his parents who lived there from 1949 until 1953.
Children with the FOLR1 mutation are born healthy. Symptoms typically appear at about 5 to 24 months of age. The symptoms get worse with time. Without treatment there may be poor muscle tone, trouble with coordination, trouble talking, and seizures. In addition, signs of psychomotor retardation, sleep disturbances, cerebellar ataxia, and delayed development of head growth can occur. At around age three, visual disturbances can develop, and sensorineural hearing loss can occur at around age six. In cerebral folate deficiency, the brain does not receive a proper supply of 5-MTHF and fails to properly grow. There may be visible loss of white matter in the brain (leukodystrophy) upon imaging.
The PCR is prepared as usual (see PCR), and the reporter probe is added. As the reaction commences, during the annealing stage of the PCR both probe and primers anneal to the DNA target. Polymerisation of a new DNA strand is initiated from the primers, and once the polymerase reaches the probe, its 5'-3'-exonuclease degrades the probe, physically separating the fluorescent reporter from the quencher, resulting in an increase in fluorescence. Fluorescence is detected and measured in a real-time PCR machine, and its geometric increase corresponding to exponential increase of the product is used to determine the quantification cycle (Cq) in each reaction.
Sources: en.wikipedia.org
Scaffolds are used to display the heterologous protein on the bacterial cell surface. There are various scaffolds which have been used such as outer membrane proteins, fimbriae/flagella proteins and CPX (circularly permuted OmpX). The CPX scaffold allows peptide fusion at both termini of the scaffold. OMPs are common scaffolds for bacterial display. Proteins can also be displayed on the bacterial cell surface through the use of autotransporters. Autotransporters form part of the type V secretion system. They usually have three domains: leader sequence at the N-terminal; central passenger domain; autotransporter domain at the C-terminal. The heterologous protein is inserted at the passenger domain. Another method of heterologous protein fusion is fusion with fimbriae/flagella, which are filamentous protrusions on the cell surface. There are many fimbriae on mainly Gram-negative bacteria, so displaying proteins on fimbriae is advantageous over some other surface proteins which are less numerous. A disadvantage of using fimbriae is that there is a relatively small insert size limit of 10-30 amino acids.
All nuclear data not otherwise stated is from the standard source: Twenty isotopes of californium are known with mass number ranging from 237 to 256; the most stable are 251Cf with half-life 898 years, 249Cf with half-life 351 years, 250Cf at 13.08 years, and 252Cf at 2.645 years. All other isotopes have half-life shorter than a year, and most of these have half-lives less than 20 minutes. 249Cf is formed by beta decay of berkelium-249, and heavier californium isotopes are made by subjecting berkelium to intense neutron radiation in a nuclear reactor. Though californium-251 has the longest half-life, its production yield is relatively low due to its rapid depletion by reaction with another neutron (high neutron cross section). 252Cf is a very strong neutron emitter, which makes it an extremely hazardous radioactive isotope. 252Cf, 96.9% of the time, alpha decays to curium-248; the other 3.1% of decays are spontaneous fission. One microgram of 252Cf emits 2.3 million neutrons per second (about 3.7 neutrons per fission). The other main isotopes of californium (248-251) also alpha decay to those of curium, with a much smaller fraction of fission.
This is normally achieved through regular blood tests, although continuous blood sugar testing equipment (Continuous Glucose Monitors or CGMs) are now becoming available which could help to refine this balancing act once widespread usage becomes common.
In 2010, Latynina criticised the Tagliavini report, saying: "A war, it turns out, is begun by he [sic] who responds to the actions of an aggressor [...]. So when Ossetian 'volunteers' burn Georgian villages - that is not a war. But if they [the Georgians] respond to this, then here you, accursed ones, have started a war." Latynina argued that according to the Tagliavini mission "Georgia had no right to send a single shell into the city [of Tskhinvali]. But the opposite side had a right to burn down Nuli, and that was not an infringement of human rights." Latynina concluded that the commission showed a "cowardice" before "an international hooligan" Vladimir Putin. Latynina called the report "a new Munich Agreement" and stated that "The prevailing motive in the report was to avoid at all costs spoiling relations with Russia". Latynina again criticised Tagliavini for the report during the events in Crimea in 2014, and again in 2015.
=== Gold nanoparticles in wound healing applications === In 2016, a paper published in the Journal of Biomaterials Application, titled "Collagen/gold nanoparticle composites: A potential skin wound healing biomaterial," discussed that in vivo studies of gold nanoparticle and collagen composites demonstrated high wound closure percentage, reduced inflammatory response, increased neovascularization, and granulation tissue formation. It was also shown that these improvements in healing effects increase proportionally with the amount of gold nanoparticles worked into the collagen scaffold. In another study, the effect of spherical gold nanoparticles as a wound healing agent was tested in rat model by coupling gold nanoparticles with photobiomodulation therapy (PBMT). PBMT is a light stimulated therapy that is used for wound healing treatment without any significant temperature changes. The coupling of gold nanoparticles and PBMT increase the wound contraction rate by approximately 1.25 times than the control group that received no gold. nanoparticle treatment.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.